{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:11:55Z","timestamp":1788930715749,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Education and teaching reform research and practice project of Zhengzhou University","award":["2024ZZUJGXM-LXS028"],"award-info":[{"award-number":["2024ZZUJGXM-LXS028"]}]},{"name":"Nature Sciences Foundation of Henan Province","award":["262300420189, 242300421411 ,252300423917"],"award-info":[{"award-number":["262300420189, 242300421411 ,252300423917"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03357-9","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:02:40Z","timestamp":1787202160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Na","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"3","key":"3357_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3357_CR2","first-page":"89","volume":"14","author":"T Prashanth Rawla","year":"2019","unstructured":"Prashanth Rawla T, Sunkara A, Barsouk. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89\u2013103.","journal-title":"Prz Gastroenterol"},{"issue":"1","key":"3357_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12964-023-01430-8","volume":"22","author":"H Amin Kamrani","year":"2024","unstructured":"Amin Kamrani H, Nasiri A, Hassanzadeh, et al. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal. 2024;22(1):56.","journal-title":"Cell Commun Signal"},{"issue":"9","key":"3357_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol"},{"issue":"26","key":"3357_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"T Dung","year":"2015","unstructured":"Dung T, Le JN, Uram H, Wang, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"6349","key":"3357_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"T Dung","year":"2017","unstructured":"Dung T, Le JN, Durham, Kellie N, Smith, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"1","key":"3357_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"J Nicolas","year":"2015","unstructured":"Nicolas J, Llosa M, Cruise A, Tam, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351.","journal-title":"Cancer Discov"},{"issue":"1","key":"3357_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"T Dung","year":"2020","unstructured":"Dung T, Le TW, Kim E, Van Cutsem, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3357_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-18-0683","volume":"7","author":"D Carino Gurjao","year":"2019","unstructured":"Carino Gurjao D, Liu M, Hofree, et al. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019;7(8):1230\u20136.","journal-title":"Cancer Immunol Res"},{"key":"3357_CR10","doi-asserted-by":"crossref","unstructured":"Emilie Picard, Chris P, Verschoor, Grace W, Ma, et al. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol. 2020;6:11369.","DOI":"10.3389\/fimmu.2020.00369"},{"issue":"7","key":"3357_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/hmg\/10.7.735","volume":"10","author":"P Peltom\u00e4ki","year":"2001","unstructured":"Peltom\u00e4ki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10(7):735\u201340.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"3357_CR12","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI82416","volume":"125","author":"J Cyrille","year":"2015","unstructured":"Cyrille J, Cohen JJ, Gartner M, Horovitz-Fried, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981\u201391.","journal-title":"J Clin Invest"},{"issue":"1","key":"3357_CR13","first-page":"1","volume":"39","author":"S Daniel","year":"2013","unstructured":"Daniel S, Chen I, Mellman. Oncology meets immunology: the cancer-immunity cycle. Immun Immun. 2013;39(1):1\u201310.","journal-title":"Immun Immun"},{"issue":"5","key":"3357_CR14","doi-asserted-by":"publisher","first-page":"e1115943","DOI":"10.1080\/2162402X.2015.1115943","volume":"5","author":"P Maby","year":"2015","unstructured":"Maby P, Galon J\u00e9r\u00f4me, Latouche J-B. Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology. 2015;5(5):e1115943.","journal-title":"Oncoimmunology"},{"issue":"17","key":"3357_CR15","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.3390\/ijms231710131","volume":"23","author":"Aude-H\u00e9l\u00e8ne","year":"2022","unstructured":"Aude-H\u00e9l\u00e8ne, Capietto. Reyhane Hoshyar, L\u00e9lia Delamarre. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. Int J Mol Sci. 2022;23(17):10131.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3357_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-025-00877-w","volume":"14","author":"Y-H Lv","year":"2025","unstructured":"Lv Y-H, He Y-C, Dai X-Y, et al. Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy. Biomark Res. 2025;14(1):4.","journal-title":"Biomark Res"},{"issue":"1","key":"3357_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41598-018-36840-z","volume":"9","author":"K Susan","year":"2019","unstructured":"Susan K, Rathe FE, Popescu JE, Johnson, et al. Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. Sci Rep. 2019;9(1):358.","journal-title":"Sci Rep"},{"issue":"18","key":"3357_CR18","first-page":"6868","volume":"61","author":"BS Worley","year":"2001","unstructured":"Worley BS, van den LT, Broeke TJ, Goletz, et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001;61(18):6868\u201375.","journal-title":"Cancer Res"},{"key":"3357_CR19","doi-asserted-by":"crossref","unstructured":"Sarah A, Penny JG, Abelin, Stacy A, Malaker, et al. Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived from Cancer Signaling in Colorectal Cancer. Front Immunol. 2021;24:12723566.","DOI":"10.3389\/fimmu.2021.723566"},{"issue":"5","key":"3357_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/2326-6066.CIR-16-0280","volume":"5","author":"A Stacy","year":"2017","unstructured":"Stacy A, Malaker SA, Penny, Lora G, Steadman, et al. Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. Cancer Immunol Res. 2017;5(5):376\u201384.","journal-title":"Cancer Immunol Res"},{"key":"3357_CR21","doi-asserted-by":"crossref","unstructured":"Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17(6):405\u201315.","DOI":"10.1097\/PPO.0b013e318237e408"},{"issue":"5215","key":"3357_CR22","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.7761852","volume":"268","author":"S Markowitz","year":"1995","unstructured":"Markowitz S, Wang J, Myeroff L, Parsons R, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268(5215):1336\u20138.","journal-title":"Science"},{"issue":"3","key":"3357_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ng1196-255","volume":"14","author":"RF Souza","year":"1996","unstructured":"Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet. 1996;14(3):255\u20137.","journal-title":"Nat Genet"},{"issue":"6591","key":"3357_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/382499a0","volume":"382","author":"S Malkhosyan","year":"1996","unstructured":"Malkhosyan S, Rampino N, Yamamoto H, et al. Frameshift mutator mutations. Nature. 1996;382(6591):499\u2013500.","journal-title":"Nature"},{"issue":"5302","key":"3357_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.275.5302.967","volume":"275","author":"N Rampino","year":"1997","unstructured":"Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275(5302):967\u20139.","journal-title":"Science"},{"issue":"12","key":"3357_CR26","first-page":"2995","volume":"59","author":"S Schwartz Jr","year":"1999","unstructured":"Schwartz S Jr, Yamamoto H, Navarro M, et al. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59(12):2995\u20133002.","journal-title":"Cancer Res"},{"issue":"17","key":"3357_CR27","first-page":"4213","volume":"59","author":"A Duval","year":"1999","unstructured":"Duval A, Gayet J, Zhou XP, et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res. 1999;59(17):4213\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"3357_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.1298","volume":"93","author":"M Linnebacher","year":"2001","unstructured":"Linnebacher M, Gebert J, Rudy W, et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001;93(1):6\u201311.","journal-title":"Int J Cancer"},{"issue":"9","key":"3357_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s002620100222","volume":"50","author":"I Saeterdal","year":"2001","unstructured":"Saeterdal I, Gjertsen MK, Straten P, et al. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8\u2009+\u2009T cells. Cancer Immunol Immunother. 2001;50(9):469\u201376.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3357_CR30","doi-asserted-by":"publisher","first-page":"e1302631","DOI":"10.1080\/2162402X.2017.1302631","volume":"6","author":"M Else","year":"2017","unstructured":"Else M, Inderberg S\u00e9bastien, W\u00e4lchli, Marit R, Myhre, et al. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology. 2017;6(4):e1302631.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3357_CR31","doi-asserted-by":"publisher","first-page":"e006001","DOI":"10.1136\/jitc-2022-006001","volume":"11","author":"L Natalia Plewa","year":"2023","unstructured":"Natalia Plewa L, Poncette T, Blankenstein. Generation of TGF\u03b2R2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy. J Immunother Cancer. 2023;11(2):e006001.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"3357_CR32","first-page":"5564","volume":"63","author":"T Toshiaki Ishikawa","year":"2003","unstructured":"Toshiaki Ishikawa T, Fujita Y, Suzuki, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. 2003;63(17):5564\u201372.","journal-title":"Cancer Res"},{"issue":"5","key":"3357_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1023\/A:1025329819121","volume":"23","author":"M Eva Ripberger","year":"2003","unstructured":"Eva Ripberger M, Linnebacher Y, Schwitalle, et al. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol. 2003;23(5):415\u201323.","journal-title":"J Clin Immunol"},{"key":"3357_CR34","unstructured":"Yvette Schwitalle M, Linnebacher E, Ripberger et al. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 2004;25:414."},{"issue":"11","key":"3357_CR35","doi-asserted-by":"publisher","first-page":"e26517","DOI":"10.1371\/journal.pone.0026517","volume":"6","author":"C Yvette Garbe","year":"2011","unstructured":"Yvette Garbe C, Maletzki M, Linnebacher. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8\u2009+\u2009cytotoxic T cell epitopes. PLoS ONE. 2011;6(11):e26517.","journal-title":"PLoS ONE"},{"issue":"12","key":"3357_CR36","doi-asserted-by":"publisher","first-page":"e16012","DOI":"10.1371\/journal.pone.0016012","volume":"5","author":"S David","year":"2010","unstructured":"David S, Williams MJ, Bird, Robert N, Jorissen, et al. Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS ONE. 2010;5(12):e16012.","journal-title":"PLoS ONE"},{"issue":"9","key":"3357_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/jnci\/90.9.675","volume":"90","author":"HJ Andreyev","year":"1998","unstructured":"Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J Natl Cancer Inst. 1998;90(9):675\u201384.","journal-title":"J Natl Cancer Inst"},{"issue":"6120","key":"3357_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/327293a0","volume":"327","author":"JL Bos","year":"1987","unstructured":"Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293\u20137.","journal-title":"Nature"},{"issue":"4","key":"3357_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/sj.bjc.6600697","volume":"88","author":"Y Shono","year":"2003","unstructured":"Shono Y, Tanimura H, Iwahashi M, et al. Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. Br J Cancer. 2003;88(4):530\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"3357_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/gutjnl-2015-309453","volume":"66","author":"C Daniele Mennonna","year":"2017","unstructured":"Daniele Mennonna C, Maccalli MC, Romano, et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut. 2017;66(3):454\u201363.","journal-title":"Gut"},{"issue":"5","key":"3357_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s43018-021-00197-6","volume":"2","author":"J Jared","year":"2021","unstructured":"Jared J, Gartner MR, Parkhurst A, Gros, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Nat Cancer. 2021;2(5):563\u201374.","journal-title":"Nat Cancer"},{"issue":"8","key":"3357_CR42","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/2159-8290.CD-20-0555","volume":"11","author":"I Jeremy Bigot, Ana","year":"2021","unstructured":"Jeremy Bigot, Ana I, Lalanne F, Lucibello, et al. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021;11(8):1938\u201351.","journal-title":"Cancer Discov"},{"key":"3357_CR43","doi-asserted-by":"crossref","unstructured":"Paul J, Gardina TA, Clark B, Shimada et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006;27:7325.","DOI":"10.1186\/1471-2164-7-325"},{"key":"3357_CR44","doi-asserted-by":"crossref","unstructured":"Kasper Thorsen, Karina D, S\u00f8rensen et al. Anne Sofie Brems-Eskildsen,. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 2008;7(7):1214-24.","DOI":"10.1074\/mcp.M700590-MCP200"},{"issue":"1","key":"3357_CR45","first-page":"71","volume":"9","author":"C-X Li","year":"2022","unstructured":"Li C-X, Wang J-S, Wang W-N, et al. Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity. Mil Med Res. 2022;9(1):71.","journal-title":"Mil Med Res"},{"key":"3357_CR46","doi-asserted-by":"crossref","unstructured":"Xu T, Verhagen M, Joosten R et al. Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behavior in colon cancer. Elife 2022;8:11: e82006.","DOI":"10.7554\/eLife.82006"},{"issue":"11","key":"3357_CR47","doi-asserted-by":"publisher","first-page":"e1113","DOI":"10.1002\/ctm2.1113","volume":"12","author":"Y-J Pan","year":"2022","unstructured":"Pan Y-J, Huo F-C, Kang M-J, et al. Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer. Clin Transl Med. 2022;12(11):e1113.","journal-title":"Clin Transl Med"},{"issue":"10","key":"3357_CR48","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/ijc.33758","volume":"149","author":"R Yasushi Mochizuki","year":"2021","unstructured":"Yasushi Mochizuki R, Funayama M, Shirota, et al. Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer. Int J Cancer. 2021;149(10):1787\u2013800.","journal-title":"Int J Cancer"},{"issue":"3","key":"3357_CR49","doi-asserted-by":"publisher","first-page":"e008402","DOI":"10.1136\/jitc-2023-008402","volume":"12","author":"Y Ren","year":"2024","unstructured":"Ren Y, Manoharan T, Liu B, et al. Circular RNA as a source of neoantigens for cancer vaccines. J Immunother Cancer. 2024;12(3):e008402.","journal-title":"J Immunother Cancer"},{"issue":"7662","key":"3357_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"E Ugur Sahin","year":"2017","unstructured":"Ugur Sahin E, Derhovanessian M, Miller, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"2","key":"3357_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00002371-199903000-00007","volume":"22","author":"SN Khleif","year":"1999","unstructured":"Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother. 1999;22(2):155\u201365.","journal-title":"J Immunother"},{"issue":"9","key":"3357_CR52","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00262-008-0477-6","volume":"57","author":"M Antoun Toubaji","year":"2008","unstructured":"Antoun Toubaji M, Achtar M, Provenzano, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother. 2008;57(9):1413\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"3357_CR53","doi-asserted-by":"crossref","unstructured":"Osama E, Rahma JM, Hamilton M, Wojtowicz, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;24:1255.","DOI":"10.1186\/1479-5876-12-55"},{"issue":"11","key":"3357_CR54","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"A Zev","year":"2025","unstructured":"Zev A, Wainberg CD, Weekes M, Furqan, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025;31(11):3648\u201353.","journal-title":"Nat Med"},{"issue":"4","key":"3357_CR55","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1053\/j.gastro.2021.06.073","volume":"161","author":"J Gebert","year":"2021","unstructured":"Gebert J, Gelincik O, Oezcan-Wahlbrink M, et al. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity with Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology. 2021;161(4):1288\u2013e130213.","journal-title":"Gastroenterology"},{"issue":"17","key":"3357_CR56","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","volume":"26","author":"M Kloor","year":"2020","unstructured":"Kloor M, Reuschenbach M, Pauligk C, et al. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I\/IIa Clinical Trial. Clin Cancer Res. 2020;26(17):4503\u201310.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3357_CR57","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"D Christine","year":"2022","unstructured":"Christine D, Palmer AR, Rappaport, Matthew J, Davis, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619\u201329.","journal-title":"Nat Med"},{"issue":"4","key":"3357_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s43018-022-00352-7","volume":"3","author":"J Longchao Liu","year":"2022","unstructured":"Longchao Liu J, Chen H, Zhang, et al. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer. 2022;3(4):437\u201352.","journal-title":"Nat Cancer"},{"issue":"12","key":"3357_CR59","doi-asserted-by":"publisher","first-page":"eaaw6071","DOI":"10.1126\/sciadv.aaw6071","volume":"6","author":"Q Ni","year":"2020","unstructured":"Ni Q, Zhang F, Liu Y, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6(12):eaaw6071.","journal-title":"Sci Adv"},{"key":"3357_CR60","doi-asserted-by":"crossref","unstructured":"Reardon S. First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment. Nature. 2024, March 11.","DOI":"10.1038\/d41586-024-00673-w"},{"issue":"23","key":"3357_CR61","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255\u201362.","journal-title":"N Engl J Med"},{"issue":"3","key":"3357_CR62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"G Andrew","year":"2014","unstructured":"Andrew G, Stephen D, Esposito, Rachel K, Bagni, et al. Dragging ras back in the ring. Cancer Cell. 2014;25(3):272\u201381.","journal-title":"Cancer Cell"},{"issue":"2","key":"3357_CR63","doi-asserted-by":"publisher","first-page":"e006822","DOI":"10.1136\/jitc-2023-006822","volume":"12","author":"A Rodabe Amaria","year":"2024","unstructured":"Rodabe Amaria A, Knisely D, Vining, et al. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024;12(2):e006822.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3357_CR64","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","volume":"5","author":"X Jiahao Liu","year":"2024","unstructured":"Jiahao Liu X, Ma JD, et al. CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors. Med. 2024;5(6):530\u201349.","journal-title":"Med"},{"issue":"11","key":"3357_CR65","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"B Theodora Anagnostou, Irbaz","year":"2020","unstructured":"Theodora Anagnostou, Irbaz B, Riaz, Shahrukh K, Hashmi, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816\u201326.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3357_CR66","doi-asserted-by":"publisher","first-page":"e010581","DOI":"10.1136\/jitc-2024-010581","volume":"13","author":"X-N Li","year":"2025","unstructured":"Li X-N, Wang F, Chen K, et al. XCL1-secreting CEA CAR-T cells enhance endogenous CD8\u2009+\u2009T cell responses to tumor neoantigens to confer a long-term antitumor immunity. J Immunother Cancer. 2025;13(1):e010581.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"3357_CR67","doi-asserted-by":"publisher","first-page":"e009960","DOI":"10.1136\/jitc-2024-009960","volume":"12","author":"D Changsong Qi","year":"2024","unstructured":"Changsong Qi D, Liu C, Liu, et al. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. J Immunother Cancer. 2024;12(10):e009960.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"3357_CR68","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224\u201334.","journal-title":"Nat Med"},{"issue":"1","key":"3357_CR69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12876-024-03286-9","volume":"24","author":"N Siheng Zeng","year":"2024","unstructured":"Siheng Zeng N, Jin B, Yu, et al. Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer. BMC Gastroenterol. 2024;24(1):249.","journal-title":"BMC Gastroenterol"},{"issue":"84","key":"3357_CR70","first-page":"301","volume":"15","author":"AE Bo Xiang","year":"2013","unstructured":"Bo Xiang AE, Snook MS, Magee, et al. Colorectal cancer immunotherapy. Discov Med. 2013;15(84):301\u20138.","journal-title":"Discov Med"},{"issue":"5","key":"3357_CR71","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. Mol Ther. 2017;25(5):1248\u201358.","journal-title":"Mol Ther"},{"issue":"3","key":"3357_CR72","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/oncolo\/oyab038","volume":"27","author":"J Damie","year":"2022","unstructured":"Damie J, Juat SJ, Hachey J, Billimek, et al. Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review. Oncologist. 2022;27(3):210\u20139.","journal-title":"Oncologist"},{"issue":"9","key":"3357_CR73","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","volume":"30","author":"SL Maria Parkhurst","year":"2024","unstructured":"Maria Parkhurst SL, Goff, Frank J, Lowery, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat Med. 2024;30(9):2586\u201395.","journal-title":"Nat Med"},{"issue":"1","key":"3357_CR74","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","volume":"13","author":"A Poole","year":"2022","unstructured":"Poole A, Karuppiah V, Hartt A, et al. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nat Commun. 2022;13(1):5333.","journal-title":"Nat Commun"},{"issue":"6291","key":"3357_CR75","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"M Erlend Str\u00f8nen","year":"2016","unstructured":"Erlend Str\u00f8nen M, Toebes S, Kelderman, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337\u201341.","journal-title":"Science"},{"issue":"12","key":"3357_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00262-025-04209-7","volume":"74","author":"A Sette","year":"2025","unstructured":"Sette A, Carri I, Marrama D, et al. A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities. Cancer Immunol Immunother. 2025;74(12):362.","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"3357_CR77","doi-asserted-by":"publisher","first-page":"e146356","DOI":"10.1172\/jci.insight.146356","volume":"6","author":"S Tomomi Hirama","year":"2021","unstructured":"Tomomi Hirama S, Tokita M, Nakatsugawa, et al. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue. JCI Insight. 2021;6(14):e146356.","journal-title":"JCI Insight"},{"key":"3357_CR78","doi-asserted-by":"crossref","unstructured":"Adriana Marques Patr\u00edcia, Cavaco C, Torre et al. Tumor mutational burden in colorectal cancer: Implications for treatment. Crit Rev Oncol Hematol. 2024 May: 197:104342.","DOI":"10.1016\/j.critrevonc.2024.104342"},{"issue":"1","key":"3357_CR79","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1186\/s12885-018-4639-4","volume":"18","author":"MB Mogensen","year":"2018","unstructured":"Mogensen MB, Rossing M, \u00d8strup O, et al. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer. 2018;18(1):752.","journal-title":"BMC Cancer"},{"issue":"6","key":"3357_CR80","first-page":"668","volume":"6","author":"E Brooke","year":"2015","unstructured":"Brooke E, Sylvester E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol. 2015;6(6):668\u201375.","journal-title":"J Gastrointest Oncol"},{"issue":"45","key":"3357_CR81","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904\u201312.","journal-title":"Oncogene"},{"issue":"4","key":"3357_CR82","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"Weiping Zou","year":"2005","unstructured":"Weiping Zou. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263\u201374.","journal-title":"Nat Rev Cancer"},{"key":"3357_CR83","doi-asserted-by":"crossref","unstructured":"Ozcan M et al. Jonas Janikovits, Magnus von Knebel Doeberitz,. Complex pattern of immune evasion in MSI colorectal cancer. Oncoimmunology. 2018;7(7): e1445453.","DOI":"10.1080\/2162402X.2018.1445453"},{"issue":"2","key":"3357_CR84","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ijc.11681","volume":"109","author":"A Derek Atkins","year":"2004","unstructured":"Derek Atkins A, Breuckmann, Gerd E, Schmahl, et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004;109(2):265\u201373.","journal-title":"Int J Cancer"},{"issue":"3","key":"3357_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1034\/j.1399-0039.2003.00020.x","volume":"61","author":"CM Cabrera","year":"2003","unstructured":"Cabrera CM, Jim\u00e9nez P, Cabrera T, Esparza C, et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7\/TAP2 downregulation in MSI-negative tumors. Tissue Antigens. 2003;61(3):211\u20139.","journal-title":"Tissue Antigens"},{"issue":"12","key":"3357_CR86","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0960-9822(02)70795-1","volume":"6","author":"DC Bicknell","year":"1996","unstructured":"Bicknell DC, Kaklamanis L, Hampson R, et al. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol. 1996;6(12):1695\u20137.","journal-title":"Curr Biol"},{"issue":"12","key":"3357_CR87","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1016\/j.ymthe.2023.10.021","volume":"31","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zuo B. Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy. Mol Ther. 2023;31(12):3579\u201393.","journal-title":"Mol Ther"},{"issue":"673","key":"3357_CR88","doi-asserted-by":"publisher","first-page":"eabn6056","DOI":"10.1126\/scitranslmed.abn6056","volume":"14","author":"M Shingo Matsushima","year":"2022","unstructured":"Shingo Matsushima M, Ajiro K, Iida, et al. Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci Transl Med. 2022;14(673):eabn6056.","journal-title":"Sci Transl Med"},{"issue":"5","key":"3357_CR89","doi-asserted-by":"publisher","first-page":"e24436","DOI":"10.4161\/onci.24436","volume":"2","author":"S Aaron","year":"2013","unstructured":"Aaron S, Mansfield WK, Nevala E, Ann T, Lieser, et al. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013;2(5):e24436.","journal-title":"Oncoimmunology"},{"issue":"5","key":"3357_CR90","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"A Leisha","year":"2015","unstructured":"Leisha A, Emens G, Middleton. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"3357_CR91","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"J Lorenzo Galluzzi","year":"2020","unstructured":"Lorenzo Galluzzi J, Humeau A, Buqu\u00e9, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3357_CR92","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"A Lorenzo Galluzzi","year":"2015","unstructured":"Lorenzo Galluzzi A, Buqu\u00e9 O, Kepp, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. cancer cell. 2015;28(6):690\u2013714.","journal-title":"Cancer Cell"},{"issue":"6","key":"3357_CR93","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/cancers12061641","volume":"12","author":"H William","year":"2020","unstructured":"William H, Gmeiner. Fluoropyrimidine modulation of the anti-tumor immune response-prospects for improved colorectal cancer treatment. Cancers (Basel). 2020;12(6):1641.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3357_CR94","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/cmi.2013.59","volume":"11","author":"B Hongliang Fang","year":"2014","unstructured":"Hongliang Fang B, Ang X, Xu, et al. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol. 2014;11(2):150\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"3357_CR95","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"Gr\u00e9goire Julie Vincent","year":"2010","unstructured":"Julie Vincent Gr\u00e9goire, Mignot F, Chalmin, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.","journal-title":"Cancer Res"},{"issue":"11","key":"3357_CR96","doi-asserted-by":"publisher","first-page":"e7669","DOI":"10.1371\/journal.pone.0007669","volume":"4","author":"L Christina","year":"2009","unstructured":"Christina L, Roland KD, Lynn JE, Toombs, et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE. 2009;4(11):e7669.","journal-title":"PLoS ONE"},{"issue":"2","key":"3357_CR97","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"O Thibault Voron","year":"2015","unstructured":"Thibault Voron O, Colussi E, Marcheteau, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8\u2009+\u2009T cells in tumors. J Exp Med. 2015;212(2):139\u201348.","journal-title":"J Exp Med"},{"issue":"3","key":"3357_CR98","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"G Shom Goel, Dan","year":"2011","unstructured":"Shom Goel, Dan G, Duda L, Xu, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071\u2013121.","journal-title":"Physiol Rev"},{"key":"3357_CR99","doi-asserted-by":"crossref","unstructured":"Jeffrey J, Wallin JC, Bendell R, Funke et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016;30:712624.","DOI":"10.1038\/ncomms12624"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03357-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:03:31Z","timestamp":1788930211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":99,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3357"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03357-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declaration"}}],"article-number":"246"}}